A phase 2 trial of the efficacy and safety of elotuzumab in combination with pomalidomide, carfilzomib and dexamethasone for high-risk relapsed/refractory multiple myeloma
Article in Leukemia & Lymphoma (November 2021)
The most recent citing publications are shown below. View all 28 publications that cite this research output on Dimensions.
Article in Leukemia & Lymphoma (November 2021)
Article in International Journal of Peptide Research and Therapeutics (September 2021)
Article in Cancers (August 2021)